Current report No. 49/2021 – Change in the composition of the Management Board of Celon Pharma S.A.

Date: November 30, 2021, time: 12:55 p.m.

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

The Management Board of Celon Pharma S.A. (hereinafter: the “Company”) hereby informs that today it has been notified of Ms Iwona Giedronowicz’s resignation from the position of member of the Company’s Management Board. Ms Iwona Giedronowicz held the position of member of the Company’s Management Board and Chief Financial Officer since 2014.

Additionally, the Company’s Management Board hereby informs that on November 30, 2021, the Company’s Supervisory Board adopted a resolution on the appointment of Ms Dorota Zwolińska to the Management Board. She will commence her role as Member of the Management Board and Chief Financial Officer as of December 15, 2021. Ms Dorota Zwolińska is a manager with many years of experience in building and managing financial structures, in particular in controlling. She graduated from the Warsaw School of Economics with a degree in Finance and Banking and is a member of the ACCA (Association of Chartered Certified Accountants).

In the course of her long career, Ms Dorota Zwolińska worked at EY (formerly Ernst&Young), where she participated in numerous financial due diligence processes conducted for M&A transactions between 2006 and 2013. Between 2013 and 2016, as Deputy Director at PKP CARGO S.A., she was responsible for building the operational and financial controlling function. She held the position of Member of the Supervisory Board of PKP Cargotabor sp. z o.o. from 2014 to 2016. She was employed at RADPOL S.A. from 2016 to 2021, where, as CFO, she was responsible in particular for liquidity, external financing, net working capital management and building the company's controlling function.

In the opinion of the Supervisory Board, the new Member joining the Company's Management Board will allow for optimisation of cost processes in the Company and is a good match for the Company's broader business development strategy.